Evaluate

December 01, 2022

US FDA approval tracker: November 2022

October 31, 2022

Go or no go? Apellis eyes an FDA outcome

Immunogen and Uniqure are also set for Pdufa conclusions.

May 17, 2022

Shionogi pays up for rare novel antifungal

July 02, 2021

US FDA approval tracker: June

May 27, 2021

Go or no go? Aducanumab’s day of reckoning

Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.

February 02, 2017

IPO bumps slow, but no need to panic yet

June 21, 2016

Interview – F2G’s novel antifungal brings in the bucks

November 30, 2015

Basilea pins future on speciality business and US float

May 11, 2015

Biotech valuation more than doubling the day of an IPO